MRK · 10-Q · 2026Q2

Merck & Co., Inc.

Filed 2026-08-07 · Healthcare · View original filing on EDGAR

Ranked Events

• Competition and Pricing PressureImportance 78 · Surprise 74
  Competitive pressure and loss of exclusivity materially reduced sales of Januvia/Janumet, Dificid, and Lagevrio, while generic competition also weakened international Bridion demand and contributed to Vaxneuvance…
• Liquidity and Debt PositionImportance 76 · Surprise 56
  Cash and investments declined to $8.363 billion at June 30, 2026 from $15.521 billion at December 31, 2025, while working capital declined to $8.948 billion from $15.189 billion. Operating cash flow increased to $9.3…
• Acquisitions and DivestituresImportance 71 · Surprise 60
  Merck recorded significant business-development charges of $5.7 billion for the Terns acquisition and $9.0 billion for the Cidara acquisition during the first six months of 2026. The Terns transaction involved…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Merck acquired TARGAN in July 2026 for approximately $650 million to expand Merck Animal Health’s poultry portfolio with WingScan automated gender identification and precision ocular spray technology. Merck acquired…
• Outstanding IndebtednessImportance 66 · Surprise 48
  Merck drew the full $6.0 billion available under a 364-day delayed-draw term loan facility in April 2026 to fund part of the approximately $6.8 billion cash consideration for Terns, and subsequently repaid the…
• Income Tax Rate ChangesImportance 65 · Surprise 82
  Merck reported a $654 million income tax provision on a $683 million pretax loss in the second quarter of 2026, producing a negative 95.9% effective tax rate. The Terns acquisition charge created a 108.9…
• Headcount / RestructuringImportance 64 · Surprise 42
  Merck’s 2025 Restructuring Program will eliminate selected sales, administrative, and R&D positions, reduce the global real-estate footprint, and optimize the manufacturing network. The program is expected to be…
• Clinical Pipeline DevelopmentsImportance 61 · Surprise 42
  Tulisokibart met the primary endpoint of clinical remission in the Phase 3 ATLAS-UC induction-only study in patients with moderately to severely active ulcerative colitis and also met key secondary endpoints. A Phase 2…
• Gross Margin DriversImportance 59 · Surprise 48
  Gross margin declined to 73.5% in the second quarter of 2026 from 77.5% in the prior-year quarter and to 73.9% from 77.7% for the first six months. Cost of sales increased 24% in the quarter and 23% year to date,…
• Single-Dose HPV Vaccine ResearchImportance 58 · Surprise 42
  Merck is collaborating with the U.S. National Cancer Institute and Agencia Costarricense de Investigaciones Biomédicas to extend the Costa Rica ESCUDDO trial evaluating a single HPV vaccine dose in females ages 12 to…
• Research and Development ExpenseImportance 58 · Surprise 42
  R&D expense increased in 2026 because of higher clinical development spending, unfavorable foreign exchange, and $14.7 billion of Terns and Cidara acquisition charges across the first six months. Merck’s direct Merck…
• Guidance and OutlookImportance 57 · Surprise 50
  Merck expects alliance revenue to decline for full-year 2026 as Adempas loses U.S. market exclusivity. The company expects U.S. Bridion sales to decline following loss of market exclusivity in July 2026 and plans to…
• Revenue Performance and MixImportance 49 · Surprise 32
  Worldwide sales increased 5% year over year to $16.6 billion in the second quarter of 2026 and to $32.9 billion in the first six months of 2026. U.S. sales rose to $9.4 billion in the quarter and $18.5 billion year to…
• Vaccine Policy LitigationImportance 47 · Surprise 60
  In January 2026, the acting CDC director changed the child and adolescent immunization schedule, reducing routinely recommended vaccinations and creating categories for universal, high-risk and shared-clinical-decision…
• Operating Expense TrendsImportance 47 · Surprise 22
  SG&A expense increased 10% year over year in the second quarter of 2026 to $2.9 billion and 8% in the first six months to $5.6 billion. Higher administrative costs, including IT investments, increased promotional and…
• Regulatory RiskImportance 44 · Surprise 60
  The FDA’s emergency-use framework for COVID-19 products is being terminated following the HHS Secretary’s June 29, 2026 determination that pandemic circumstances no longer justify emergency use. Lagevrio’s U.S. EUA is…
• Capital Return ProgramImportance 42 · Surprise 14
  Merck paid $4.2 billion of dividends to stockholders in the first six months of 2026, up from $4.1 billion in the prior-year period. The Board declared quarterly dividends of $0.85 per share for the second and third…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Under its December 2025 three-year most-favored-nation (MFN) agreement with the U.S. government, Merck provides Januvia, Janumet and Janumet XR through a direct-to-patient program and plans to expand it to Lipfendra.…
• German Health-Care ReformImportance 40 · Surprise 42
  Germany’s parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG) in July 2026. Most provisions take effect January 1, 2027 and introduce cost-containment measures intended…
• Geographic Market CommentaryImportance 40 · Surprise 42
  U.S. demand was strong for Keytruda/Keytruda Qlex, Welireg, Winrevair, and Prevymis, but U.S. vaccine demand weakened and Januvia/Janumet faced competitive volume declines. Gardasil/Gardasil 9 demand grew in Europe and…

Revenue by Product (in millions)

Revenue by Geography (in millions)